Alpha 2.0
Login Register
» Authors » Cheryl Cohen

Cheryl Cohen

Explore the profile of Cheryl Cohen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 287
Citations 11419
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Microbiology
Top 10 Co-Authors
Stefano Tempia
Anne von Gottberg
Sibongile Walaza
Nicole Wolter
Jocelyn Moyes
Shabir A Madhi
Adam L Cohen
Orienka Hellferscee
Halima Dawood
Ebrahim Variava
Published In
PLoS One
Influenza Other Respir Viruses
Clin Infect Dis
Emerg Infect Dis
J Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Corynebacterium diphtheriae Infections, South Africa, 2015-2023
du Plessis M, Mikhari R, de Gouveia L, Duma N, Lovelock T, Lawrence C, et al.
Emerg Infect Dis . 2025 Mar; 31(3):417-426. PMID: 40023798
We reviewed Corynebacterium spp. infection cases reported in South Africa during 2015-2023. We analyzed 84 isolates from 83 patients with C. diphtheriae, as well as 1 C. belfantii and 3...
2.
Pathogen aetiology and risk factors for death among neonates with bloodstream infections at lower-tier South African hospitals: a cross-sectional study
Meiring S, Quan V, Mashau R, Perovic O, Magobo R, Smith M, et al.
Lancet Microbe . 2025 Feb; :100989. PMID: 40020700
Background: Infections are among the top causes of neonatal mortality, particularly in low-income and middle-income countries. We aimed to describe the clinical characteristics of neonates diagnosed with culture-confirmed bloodstream infections...
3.
Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic - the multicentre,...
Nabeemeeah F, Sabet N, Otwombe K, Hlongwane K, Mlambo L, Moloantoa T, et al.
BMJ Open . 2025 Jan; 14(12):e080553. PMID: 39806691
Purpose: In the setting of an established childhood pneumococcal vaccination programme with immediate initiation and treatment of antiretroviral therapy (ART) for people living with HIV (PLWH), the risk of adult...
4.
Costs of Influenza Illness and Acute Respiratory Infections by Household Income Level: Catastrophic Health Expenditures and Implications for Health Equity
Wodniak N, Gharpure R, Feng L, Lai X, Fang H, Tian J, et al.
Influenza Other Respir Viruses . 2025 Jan; 19(1):e70059. PMID: 39789855
Background: Seasonal influenza illness and acute respiratory infections can impose a substantial economic burden in low- and middle-income countries (LMICs). We assessed the cost of influenza illness and acute respiratory...
5.
A generalised catalytic model to assess changes in risk for multiple reinfections with SARS-CoV-2
Lombard B, Cohen C, von Gottberg A, Dushoff J, Pulliam J, van Schalkwyk C
PLoS One . 2025 Jan; 20(1):e0315476. PMID: 39746096
Background: Monitoring trends in multiple infections with SARS-CoV-2, following several pandemic waves, provides insight into the biological characteristics of new variants, but also necessitates methods to understand the risk of...
6.
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
Bennett J, Knoll M, Kagucia E, Garcia Quesada M, Zeger S, Hetrich M, et al.
Lancet Infect Dis . 2024 Dec; PMID: 39706204
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages....
7.
Home-Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021-2022-A Pilot Study
Moyes J, Makhazi M, Walaza S, Ntombela P, Moosa F, von Gottberg A, et al.
Influenza Other Respir Viruses . 2024 Dec; 18(12):e70034. PMID: 39648401
Background: Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability...
8.
A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa
Cohen C, du Plessis M, Martinson N, Moyes J, Walaza S, Wolter N, et al.
J Infect Dis . 2024 Nov; 231(2):e328-e336. PMID: 39542652
Background: Approaches for determining whether influenza vaccination prevents infection, attenuates illness, or both are important for developing improved vaccines. We estimated influenza infection incidence and evaluated symptom ascertainment methodologies in...
9.
Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 - 2018
Moyes J, Tempia S, Walaza S, Cohen A, Treurnicht F, Hellferscee O, et al.
BMC Infect Dis . 2024 Oct; 24(1):1128. PMID: 39385077
Background: Identifying risk factors for respiratory syncytial virus (RSV)-associated severe acute respiratory illness (SARI) will assist with targeting vaccine interventions. Methods: Using surveillance data from South Africa (2012-2018), we compared...
10.
Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children
Lekhuleni C, Ndlangisa K, Gladstone R, Chochua S, Metcalf B, Li Y, et al.
Nat Commun . 2024 Sep; 15(1):8401. PMID: 39333488
Invasive pneumococcal disease (IPD) due to non-vaccine serotypes after the introduction of pneumococcal conjugate vaccines (PCV) remains a global concern. This study used pathogen genomics to evaluate changes in invasive...